Biophagy initiates a new program to study its proprietary compounds in SARS-CoV-2 (covid-19). These studies will be conducted by Dr. Steven Bradfute at UNM. By jordan|2022-03-22T20:33:48+00:00February 1, 2022|2020-announcements|0 Comments Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTelegramTumblrPinterestVkXingEmail About the Author: jordan Related Posts Biophagy presents “Examining the Potency of Potential Autophagy Inducing Drugs,” at a UNM Discovery Symposium Biophagy presents “Examining the Potency of Potential Autophagy Inducing Drugs,” at a UNM Discovery Symposium Biophagy announces the addition of Bhaskar Suda, PhD, to its team of consultants. Bhaskar will develop and run autophagy measuring assays and study proprietary compounds in neurodegenerative disorders. Biophagy announces the addition of Bhaskar Suda, PhD, to its team of consultants. Bhaskar will develop and run autophagy measuring assays and study proprietary compounds in neurodegenerative disorders. Biophagy institutes a new division, CellWatch™, to develop its over-the-counter/direct-to-consumer products for the stimulation and measurement of autophagy in individuals. Biophagy institutes a new division, CellWatch™, to develop its over-the-counter/direct-to-consumer products for the stimulation and measurement of autophagy in individuals. Biophagy presents “Potential of Proprietary Molecules for Inducing Autophagy and Enhancing Antibiotic Treatment of Tuberculosis” at the Keystone Symposium, Tuberculosis: Immunity and Immune Evasion,” Santa Fe, NM Biophagy presents “Potential of Proprietary Molecules for Inducing Autophagy and Enhancing Antibiotic Treatment of Tuberculosis” at the Keystone Symposium, Tuberculosis: Immunity and Immune Evasion,” Santa Fe, NM Leave A Comment Cancel replyComment Save my name, email, and website in this browser for the next time I comment.
Leave A Comment